Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921796 | 1.00 | PDE4B (0.53) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL14921794 | 1.00 | PDE4B (0.53) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL16141292 | 1.00 | PDE4B (0.53) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL3003926 | 0.91 | PDE4B (0.53) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL3003928 | 0.91 | PDE4B (0.53) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL7914450 | 0.91 | PDE4B (0.53) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL16108128 | 0.91 | TACR3 (0.52) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL14934679 | 0.91 | TACR3 (0.52) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL16108127 | 0.91 | TACR3 (0.52) | PDE4BDPP4SCN9ATACR1GPR119 | |
| SCHEMBL16109016 | 0.90 | PDE4B (0.50) | PDE4BDPP4SCN9ATACR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | PDE4B 3544/4885DPP4 1551/4885SCN9A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.